DURAGESIC® (fentanyl transdermal system), CII
DURAGESIC® (fentanyl transdermal system), CII is an FDA-approved transdermal patch.1 DURAGESIC® has a child-resistant packaging and is part of an FDA-approved and required Risk Evaluation and Mitigation Strategy (REMS) program. The REMS program outlines strategies to manage known or potential risks associated with these products to ensure that the benefits of a drug outweigh its risks.2
We stopped promotion of this medicine in 2008 and in 2020, Janssen made the business decision to discontinue its prescription pain medications in the United States.
For more information about DURAGESIC®, click here for full prescribing information, instructions for use, and medication guide.
Find more information about DURAGESIC® in our recent court filings.
NUCYNTA® and NUCYNTA® ER (tapentadol), CII
We manufactured two forms of NUCYNTA® (tapentadol) tablets, CII - an immediate release tablet and an extended release tablet. The extended release tablet was designed to make it harder to be split, crushed or dissolved.3 Both medicines are FDA-approved and NUCYNTA® ER was launched with an FDA-approved REMS program.
We sold the U.S. NUCYNTA® brand to another manufacturer in 2015.4
For more information about NUCYNTA®, click here for full prescribing information and medication guide.5
For more information about NUCYNTA® ER, click here for full prescribing information and medication guide.6
Find more information about NUCYNTA® in our recent court filings.